Genetic Immunity Develops Nanomedicine Therapeutic Vaccine for HIV/AIDS


Genetic Immunity, a multi-national biopharmaceutical company developing nanomedicine vaccines today announces publication of the Company’s innovative work to develop a stable liquid formulation to deliver a novel nanomedicine. Appearing in the International Journal of Pharmaceutics, the paper addresses how Genetic Immunity was able to overcome significant hurdles facing the field to successfully formulate the first topically administered nanomedicine therapeutic vaccine for the treatment of HIV/AIDS, DermaVir. “Biological activity of DermaVir depends upon its nanomedicine formulation that is essential for the potent expression of plasmid-DNA-encoded antigens. During Phase I and II clinical trials, DermaVir formulation required on-site admixture of three separate components followed by patient administration within three hours. We report here the development of a stable single liquid nanomedicine formulation, a significant milestone in developing DermaVir as a commercially viable global product to treat HIV/A....IDS,” commented Julianna Lisziewicz, PhD and CEO of Genetic Immunity.

-Significantly reduced CCR5-tropic HIV-1 repli...nized with Vaccinia Virus
-Provisional PDF

Background
"At present, the relatively sudden appearance and explosive spread of HIV throughout Africa and around the world beginning in the 1950s have never been adequately explained. Theorizing that this phenomenon may be somehow related to the eradication of smallpox followed by the cessation of vaccinia immunization, we undertook a comparison of HIV-1 susceptibility in the peripheral blood mononuclear cells from subjects immunized with the vaccinia virus to those from vaccinia naive donors."

Results
"Vaccinia immunization in the preceding 3-6 months resulted in an up to 5-fold reduction in CCR5-tropic but not in CXCR4-tropic HIV-1 replication in the cells from vaccinated subjects. The addition of autologous serum to the cell cultures resulted in enhanced R5 HIV-1 replication in the cells from unvaccinated, but not vaccinated subjects. There were no significant differences in the concentrations of MIP-1alpha, MIP-1beta and RANTES between the cell cultures derived from vaccinated and unvaccinated subjects when measured in culture medium on days 2 and 5 following R5 HIV-1 challenge."

Dynamic HIV testing

A relatively simple electronic gadget could speed up HIV/AIDS diagnostics and improve accuracy particularly in parts of the world with very limited access to healthcare workers. The device is described in the International Journal of Biomedical Engineering and Technology. ...

Critical Outcome Technologies discovers novel... inhibiting HIV integrase

Canada's Critical Outcome Technologies (COTI) has announced positive results from the first phase of its HIV integrase inhibitor discovery program.
The company, listed on Toronto Stock Exchange, said the significance of these results is that the majority of currently marketed and developmental stage HIV Integrase inhibitors have a very similar way of interacting with and inhibiting the enzyme through a diketo acid type moiety. COTI has used its proprietary technology, CHEMSAS, to discover several novel small molecule scaffolds that have an entirely new binding mode and interaction with the active site of the viral enzyme......

Mother-to-Child HIV Transmission Linked to Gene Change

Certain variants make it more likely babies will acquire the AIDS-causing virus, researchers say...